

Claims

1. An oral dosage form comprising oxcarbazepine adapted to be administered once a day.
- 5 2. The oral dosage form comprising oxcarbazepine according to claim 1 which, when administered once a day, is released to produce constant MHD plasma levels over 24 hours.
- 10 3. The oral dosage form according to claim 1 or 2 consisting of a tablet core and a coating wherein the core comprises oxcarbazepine, optionally, a filler, and at least one further excipient selected from cellulose ethers, carboxyvinyl polymer of acrylic acid cross linked with alkyl ethers of sucrose or pentaerythritol and polymethacrylates.
- 15 4. The oral dosage form according to claim 3 wherein a cellulose ether is employed which is hydroxypropyl methyl cellulose.
5. The oral dosage form according to claim 4 wherein the weight ratio of total hydroxypropyl-methyl cellulose to oxcarbazepine is from about 1:10 to about 1:20.
- 20 6. The oral dosage form according to claim 3 wherein a cellulose ether is employed which is ethyl cellulose.
7. The oral dosage form according to claim 6 wherein the weight ratio of total ethyl cellulose to oxcarbazepine is from about 1:10 to about 1:20.
- 25 8. The oral dosage form according to claim 3 comprising a polymethacrylate which is trimethylammonium methacrylate.
9. The oral dosage form according to any one of claims 3 to 8 comprising as a filler
30 microcrystalline cellulose.
10. The oral dosage form according to any one of claims 1 to 9 having a 80% or greater release of the oxcarbazepine dose within 1 hour indicated in standard in vitro dissolution

- 34 -

tests at 37 degrees Celsius in water using sodium dodecyl sulphate as a solubilizing agent at a concentration of 1% for a 600 mg dosage form.

- 5 11. The oral dosage form according to any one of claims 1 to 10 releasing oxcarbazepine at a constant release rate for 4 hours or more as indicated in standard in vitro dissolution tests at 37 degrees Celsius in water using sodium dodecyl sulphate as a solubilizing agent at a concentration of 1% for a 600 mg dosage form.
- 10 12. The oral dosage form according to claim 11 releasing about 80 % of oxcarbazepine within 8 hours.
13. An oral dosage form comprising oxcarbazepine which, when administered once a day, is released to produce constant MHD plasma levels over 24 hours.
- 15 14. Use of oxcarbazepine for the manufacture of an oral dosage form medicament to be administered to a patient once a day wherein oxcarbazepine is released to produce a constant profile over 24 hours for the treatment of epilepsy.
- 20 15. Use of oxcarbazepine for the manufacture of an oral dosage form medicament according to any one of claims 1 to 13 for the treatment of epilepsy.
- 25 16. A method of orally administering oxcarbazepine, e.g., for the treatment of epilepsy, said method comprising orally administering to a patient in need of oxcarbazepine therapy once-a-day an oral dosage form of any one of claims 1 to 13.
17. A method of reducing the variability of bioavailability levels of cyclosporin A for patients during oxcarbazepine therapy, said method comprising orally administering to a patient in need of oxcarbazepine therapy an oral dosage form of any one of claims 1 to 13.